- Home
- IDR vs CMPS Comparison
IDR vs CMPS Comparison
Compare IDR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | CMPS |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.6M | 724.5M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IDR | CMPS |
|---|---|---|
| Price | $38.43 | $5.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.57 |
| AVG Volume (30 Days) | 329.2K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.15 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $42,406,253.00 | N/A |
| Revenue This Year | $25.52 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.16 | ★ N/A |
| Revenue Growth | ★ 64.59 | N/A |
| 52 Week Low | $12.25 | $2.25 |
| 52 Week High | $54.70 | $8.90 |
Technical Indicators
Market Signals| Indicator | IDR | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 48.79 |
| Support Level | $38.13 | $4.90 |
| Resistance Level | $41.08 | $7.02 |
| Average True Range (ATR) | 2.27 | 0.28 |
| MACD | 1.15 | 0.07 |
| Stochastic Oscillator | 97.28 | 85.29 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.